Vontobel Holding Ltd. Has $780,000 Holdings in Seres Therapeutics, Inc. (NASDAQ:MCRB)

Vontobel Holding Ltd. grew its position in Seres Therapeutics, Inc. (NASDAQ:MCRB) by 137.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 938,295 shares of the biotechnology company’s stock after purchasing an additional 543,469 shares during the period. Vontobel Holding Ltd. owned about 0.55% of Seres Therapeutics worth $780,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Virtu Financial LLC boosted its stake in shares of Seres Therapeutics by 44.8% during the 3rd quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 18,191 shares in the last quarter. Providence Wealth Advisors LLC boosted its stake in shares of Seres Therapeutics by 29.2% during the 3rd quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company’s stock worth $93,000 after acquiring an additional 22,250 shares in the last quarter. State Street Corp boosted its stake in shares of Seres Therapeutics by 12.9% during the 3rd quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock worth $363,000 after acquiring an additional 43,700 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Seres Therapeutics by 42.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company’s stock worth $708,000 after acquiring an additional 222,771 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Seres Therapeutics by 22.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company’s stock worth $1,314,000 after acquiring an additional 255,014 shares in the last quarter. 59.34% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently issued reports on MCRB shares. Canaccord Genuity Group reiterated a “buy” rating and set a $10.00 price target on shares of Seres Therapeutics in a research note on Thursday, November 14th. StockNews.com upgraded Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 14th. JPMorgan Chase & Co. downgraded Seres Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Thursday, October 24th. Finally, Chardan Capital restated a “buy” rating and set a $1.25 target price on shares of Seres Therapeutics in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $5.08.

Seres Therapeutics Stock Down 0.2 %

Shares of Seres Therapeutics stock opened at $0.83 on Wednesday. Seres Therapeutics, Inc. has a 12 month low of $0.54 and a 12 month high of $1.53. The business has a fifty day simple moving average of $0.85 and a 200 day simple moving average of $0.86. The stock has a market cap of $141.92 million, a PE ratio of -3.61 and a beta of 2.11.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.